Abstract
Background
Though clinically similar, Ebola virus disease and Marburg virus disease are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major outbreaks (≥200 cases; five caused by Zaire ebolavirus [EBOV], two by Sudan ebolavirus [SUDV], and one by Marburg virus [MARV]). Our purpose is to develop a multivalent vaccine regimen protecting against each of these filoviruses. This first-in-human study assessed the safety and immunogenicity of several multivalent two-dose vaccine regimens that contain Ad26.Filo and MVA-BN-Filo.
Methods
Ad26.Filo combines three vaccines encoding the glycoprotein (GP) of EBOV, SUDV, and MARV. MVA-BN-Filo is a multivalent vector encoding EBOV, SUDV, and MARV GPs, and Taï Forest nucleoprotein. This Phase 1, randomized, double-blind, placebo-controlled study enrolled healthy adults (18–50 years) into four groups, randomized 5:1 (active:placebo), to assess different Ad26.Filo and MVA-BN-Filo vaccine directionality and administration intervals. The primary endpoint was safety; immune responses against EBOV, SUDV, and MARV GPs were also assessed.
Results
Seventy-two participants were randomized, and 60 (83.3%) completed the study. All regimens were well tolerated with no deaths or vaccine-related serious adverse events (AEs). The most frequently reported solicited local AE was injection site pain/tenderness. Solicited systemic AEs most frequently reported were headache, fatigue, chills, and myalgia; most solicited AEs were Grade 1–2. Solicited/unsolicited AE profiles were similar between regimens. Twenty-one days post-dose 2, 100% of participants on active regimen responded to vaccination and exhibited binding antibodies against EBOV, SUDV, and MARV GPs; neutralizing antibody responses were robust against EBOV (85.7–100%), but lower against SUDV (35.7–100%) and MARV (0–57.1%) GPs. An Ad26.Filo booster induced a rapid further increase in humoral responses.
Conclusion
This study demonstrates that heterologous two-dose vaccine regimens with Ad26.Filo and MVA-BN-Filo are well tolerated and immunogenic in healthy adults.
ClinicalTrials.gov
NCT02860650.
Funder
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services
Publisher
Public Library of Science (PLoS)
Reference31 articles.
1. World Health Organization. Ebola virus disease. [Cited 15 July 2021]. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease.
2. World Health Organization. Marburg virus disease. [Cited 15 July 2021]. https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease.
3. Ebola haemorrhagic fever in Zaire, 1976;Report of an International Commission;Bull World Health Organ,1978
4. Marburg Virus Disease
5. World Health Organization. Ebola virus disease. [Cited 15 July 2021]. https://www.who.int/csr/disease/ebola/en.